help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gründker, C.
Right arrow Articles by Emons, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gründker, C.
Right arrow Articles by Emons, G.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Ovarian Cancer
The Journal of Clinical Endocrinology & Metabolism Vol. 85, No. 10 3815-3820
Copyright © 2000 by The Endocrine Society

Original Studies

Luteinizing Hormone-Releasing Hormone Induces Nuclear Factor {kappa}B-Activation and Inhibits Apoptosis in Ovarian Cancer Cells

Carsten Gründker, Katja Schulz, Andreas R. Günthert and Günter Emons

Department of Gynecology and Obstetrics, Georg-August University, D-37070 Göttingen, Germany

Address correspondence and requests for reprints to: Günter Emons, M.D., Georg-August University, Department of Gynecology and Obstetrics, Robert-Koch Street 40, D-37075 Göttingen, Germany. E-mail: emons{at}med.uni-goettingen.de

More than 80% of human ovarian cancers express LHRH and its receptor as part of a negative autocrine mechanism of growth control. This study was conducted to investigate whether LHRH affects apoptosis in ovarian cancer. EFO-21 and EFO-27 ovarian cancer cells were treated with LHRH agonist Triptorelin or with cytotoxic agent Doxorubicin in the absence or presence of Triptorelin. Apoptotic cells were quantified by flow cytometry. Expression of nuclear factor kappa B (NF{kappa}B) was assessed by RT-PCR and immunoblotting. For determination of Triptorelin-induced NF{kappa}B activation, cells were transfected with a NF{kappa}B-secreted alkaline phosphatase reporter gene plasmid (pNF{kappa}B-SEAP) and cultured for 96 h with or without Triptorelin. The causal relation between Triptorelin-induced NF{kappa}B activation and Triptorelin-induced protection against apoptosis was investigated using SN50, an inhibitor for nuclear translocation of activated NF{kappa}B. Apoptosis induction by Triptorelin was never observed. Treatment with Doxorubicin (1 nmol/L) for 72 h increased the percentage of apoptotic cells in EFO-21 and EFO-27 ovarian cancer cell lines to 31% or 34%, respectively. In cultures treated simultaneously with Triptorelin (100 nmol/L), the percentage of apoptotic cells was reduced significantly, to 17% or 18%, respectively (P < 0.001). RT-PCR and immunoblotting experiments showed that NF{kappa}B subunits p50 and p65 were expressed by ovarian cancer cell lines EFO-21 and EFO-27. When EFO-21 or EFO-27 cells were transfected with pNF{kappa}B-SEAP and subsequently treated with Triptorelin (100 nmol/L), NF{kappa}B-induced SEAP expression increased 5.3-fold or 4.7-fold, respectively (P < 0.001). Triptorelin-induced reduction of Doxorubicin-induced apoptosis was blocked by SN50-mediated inhibition of NF{kappa}B translocation into the nucleus. We conclude that LHRH induces activation of NF{kappa}B and thus reduces Doxorubicin-induced apoptosis in human ovarian cancer cells. This possibility to protect ovarian cancer cells from programmed cell death is an important feature in LHRH signaling in ovarian tumors, apart from the inhibitory interference with the mitogenic pathway.




This article has been cited by other articles:


Home page
 Hum Reprod UpdateHome page
P. C.K. Leung and J.-H. Choi
Endocrine signaling in ovarian surface epithelium and cancer
Hum. Reprod. Update, March 1, 2007; 13(2): 143 - 162.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Fister, A. R. Gunthert, G. Emons, and C. Grundker
Gonadotropin-Releasing Hormone Type II Antagonists Induce Apoptotic Cell Death in Human Endometrial and Ovarian Cancer Cells In vitro and In vivo
Cancer Res., February 15, 2007; 67(4): 1750 - 1756.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
N. S. Macklon, R. L. Stouffer, L. C. Giudice, and B. C. J. M. Fauser
The Science behind 25 Years of Ovarian Stimulation for in Vitro Fertilization
Endocr. Rev., April 1, 2006; 27(2): 170 - 207.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
C. K. Cheng and P. C. K. Leung
Molecular Biology of Gonadotropin-Releasing Hormone (GnRH)-I, GnRH-II, and Their Receptors in Humans
Endocr. Rev., April 1, 2005; 26(2): 283 - 306.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
C. Grundker, A. Huschmand Nia, and G. Emons
Gonadotropin-releasing hormone receptor-targeted gene therapy of gynecologic cancers
Mol. Cancer Ther., February 1, 2005; 4(2): 225 - 232.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
G S Harrison, M E Wierman, T M Nett, and L M Glode
Gonadotropin-releasing hormone and its receptor in normal and malignant cells
Endocr. Relat. Cancer, December 1, 2004; 11(4): 725 - 748.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
K.-Y. Kim, K.-C. Choi, S.-H. Park, C.-S. Chou, N. Auersperg, and P. C. K. Leung
Type II Gonadotropin-Releasing Hormone Stimulates p38 Mitogen-Activated Protein Kinase and Apoptosis in Ovarian Cancer Cells
J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 3020 - 3026.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
R. P. Millar, Z.-L. Lu, A. J. Pawson, C. A. Flanagan, K. Morgan, and S. R. Maudsley
Gonadotropin-Releasing Hormone Receptors
Endocr. Rev., April 1, 2004; 25(2): 235 - 275.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. R. Finch, L. Green, J. N. Hislop, E. Kelly, and C. A. McArdle
Signaling and Antiproliferative Effects of Type I and II Gonadotropin-Releasing Hormone Receptors in Breast Cancer Cells
J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1823 - 1832.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
L. E. C. Miles, A. C. Hanyaloglu, J. R. Dromey, K. D. G. Pfleger, and K. A. Eidne
Gonadotropin-Releasing Hormone Receptor-Mediated Growth Suppression of Immortalized L{beta}T2 Gonadotrope and Stable HEK293 Cell Lines
Endocrinology, January 1, 2004; 145(1): 194 - 204.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
V. Poulaki, C. S. Mitsiades, A. M. Joussen, A. Lappas, B. Kirchhof, and N. Mitsiades
Constitutive Nuclear Factor-{kappa}B Activity Is Crucial for Human Retinoblastoma Cell Viability
Am. J. Pathol., December 1, 2002; 161(6): 2229 - 2240.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
X. Tang, T. Yano, Y. Osuga, H. Matsumi, N. Yano, J. Xu, O. Wada, K. Koga, K. Kugu, O. Tsutsumi, et al.
Cellular Mechanisms of Growth Inhibition of Human Epithelial Ovarian Cancer Cell Line by LH-Releasing Hormone Antagonist Cetrorelix
J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3721 - 3727.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
N. Mitsiades, C. S. Mitsiades, V. Poulaki, D. Chauhan, P. G. Richardson, T. Hideshima, N. Munshi, S. P. Treon, and K. C. Anderson
Biologic sequelae of nuclear factor-kappa B blockade in multiple myeloma: therapeutic applications
Blood, May 13, 2002; 99(11): 4079 - 4086.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
C. Grundker, P. Volker, and G. Emons
Antiproliferative Signaling of Luteinizing Hormone-Releasing Hormone in Human Endometrial and Ovarian Cancer Cells through G Protein {{alpha}}I-Mediated Activation of Phosphotyrosine Phosphatase
Endocrinology, June 1, 2001; 142(6): 2369 - 2380.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2000 by The Endocrine Society